drugset / Trial / NCT02934178
Shigella WRSS1 Vaccine Trial in Bangladesh
Phase 1
Completed
16 enrolled
PATH
International Centre for Diarrhoeal Disease Research, Bangladesh · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a research study of an experimental (investigational) live attenuated Shigella sonnei vaccine (WRSS1) to find a dose of the vaccine that is safe, tolerable, and develops an immune response. Shigella causes bloody and watery diarrhea, and infants and children living in developing countries experience the greatest consequences of this disease.
Timeline
- Start
- 2017-02-23
- Primary completion
- 2018-01-10
- Completion
- 2018-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WRSS1 | Vaccine | 3000 unknown | Oral |
| Subject | WRSS1 | Vaccine | 30000 unknown | Oral |
| Subject | WRSS1 | Vaccine | 300000 unknown | Oral |
| Subject | WRSS1 | Vaccine | 3e+06 unknown | Oral |